• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Pres. & Chief Exec. Officer Maetzold Derek J sold $458,293 worth of shares (22,576 units at $20.30), decreasing direct ownership by 7% to 69,683 units (SEC Form 4)

    7/1/25 4:05:26 PM ET
    $CSTL
    Medical Specialities
    Health Care
    Get the next $CSTL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    MAETZOLD DEREK J

    (Last) (First) (Middle)
    C/O CASTLE BIOSCIENCES, INC.
    505 S. FRIENDSWOOD DRIVE, SUITE 401

    (Street)
    FRIENDSWOOD TX 77546

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CASTLE BIOSCIENCES INC [ CSTL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Pres. & Chief Exec. Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    06/27/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/27/2025 S(1) 4,944 D $20.3(2) 69,683 D
    Common Stock 06/27/2025 S(1) 8,068 D $20.3(2) 52,923 I By The Maetzold Descendants 2020 Trust(3)
    Common Stock 06/27/2025 S(1) 6,924 D $20.3(2) 44,986 I By Derek Maetzold 2020 Irrevocable Trust(4)
    Common Stock 06/27/2025 S(1) 660 D $20.3(2) 3,618 I By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk(5)
    Common Stock 06/27/2025 S(1) 660 D $20.3(2) 3,615 I By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold(6)
    Common Stock 06/27/2025 S(1) 660 D $20.3(2) 3,615 I By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold(7)
    Common Stock 06/27/2025 S(1) 660 D $20.3(2) 3,615 I By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold(8)
    Common Stock 122,866 I By DJM Grantor Retained Annuity Trust No. 5(9)
    Common Stock 26,134 I By DJM Grantor Retained Annuity Trust No. 6(10)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024.
    2. This transaction was executed in multiple trades at prices ranging from $20.00 to $20.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
    3. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
    4. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
    5. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
    6. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
    7. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
    8. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
    9. Held by DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is the trustee and beneficiary.
    10. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
    Remarks:
    /s/ Frank Stokes, Attorney-in-fact 07/01/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CSTL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CSTL

    DatePrice TargetRatingAnalyst
    12/14/2023$25.00Buy
    Guggenheim
    1/5/2023$54.00Sector Outperform
    Scotiabank
    1/7/2022$59.00Overweight
    Stephens & Co.
    11/9/2021$85.00 → $75.00Outperform
    SVB Leerink
    7/14/2021$80.00 → $85.00Outperform
    SVB Leerink
    More analyst ratings

    $CSTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres. & Chief Exec. Officer Maetzold Derek J sold $458,293 worth of shares (22,576 units at $20.30), decreasing direct ownership by 7% to 69,683 units (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      7/1/25 4:05:26 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Director Cole G Bradley converted options into 8,673 shares, increasing direct ownership by 65% to 21,964 units (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 5:01:17 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Director Bradbury Daniel converted options into 8,673 shares (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 4:19:15 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    SEC Filings

    See more
    • SEC Form 144 filed by Castle Biosciences Inc.

      144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      6/27/25 6:11:51 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)

      5/23/25 4:39:01 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Castle Biosciences Inc.

      SCHEDULE 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      5/12/25 3:55:49 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

      FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces award, with Castle ranking third among other recognized companies in its size bracket; a fourth consecutive regional Arizona Top Workplaces award from AZ Central; and consecutive national Top Workplaces Culture Excellence awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values. "Being recognized as a Top Workplace, ye

      7/17/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

      FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      7/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 66 employees covering an aggregate of 135,978 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting c

      6/19/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Castle Biosciences with a new price target

      Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00

      12/14/23 6:54:55 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Scotiabank initiated coverage on Castle Biosciences with a new price target

      Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00

      1/5/23 7:53:37 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Stephens & Co. initiated coverage on Castle Biosciences with a new price target

      Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00

      1/7/22 5:42:05 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

      The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit

      4/30/24 4:30:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

      -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

      10/23/23 8:00:00 AM ET
      $CSTL
      $EQ
      $ICPT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

      SAN DIEGO, May 26, 2021  /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful

      5/26/21 12:42:00 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      11/14/24 4:40:39 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      11/13/24 6:44:33 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      7/8/24 4:32:39 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Financials

    Live finance-specific insights

    See more
    • Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

      FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      7/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Reports First Quarter 2025 Results

      Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. "We are pleased with the exceptional start to the year, marked by continued growth in test report volum

      5/5/25 4:06:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

      FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/787806709, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      4/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care